Loading…

Evaluation of nine serological rapid tests for the detection of SARS-CoV-2

Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the eval...

Full description

Saved in:
Bibliographic Details
Published in:Revista panamericana de salud pública 2020-12, Vol.44 (149), p.1-9
Main Authors: Mercado, Marcela, Malagón-Rojas, Jeadran, Delgado, Gabriela, Rubio, Vivian Vanesa, Muñoz Galindo, Lida, Parra Barrera, Eliana L., Gaviria, Paula, Zabaleta, Gabriela, Alarcon, Zonia, Arévalo, Adriana, Cifuentes, Helly Casallas, Estrada, Kelly, Puerto, Gloria, Herrera Sepúlveda, María T., Rodríguez, Helena, Galindo, Marisol, Ospina Ramírez, Martha Lucía
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3
cites cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3
container_end_page 9
container_issue 149
container_start_page 1
container_title Revista panamericana de salud pública
container_volume 44
creator Mercado, Marcela
Malagón-Rojas, Jeadran
Delgado, Gabriela
Rubio, Vivian Vanesa
Muñoz Galindo, Lida
Parra Barrera, Eliana L.
Gaviria, Paula
Zabaleta, Gabriela
Alarcon, Zonia
Arévalo, Adriana
Cifuentes, Helly Casallas
Estrada, Kelly
Puerto, Gloria
Herrera Sepúlveda, María T.
Rodríguez, Helena
Galindo, Marisol
Ospina Ramírez, Martha Lucía
description Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples. Results. The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms. Conclusions. Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.
doi_str_mv 10.26633/RPSP.2020.149
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_470c6cc78890490a92100f3454bd3185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_470c6cc78890490a92100f3454bd3185</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_7734239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</originalsourceid><addsrcrecordid>eNpVkV1LwzAUhosoOKe3XvcPdJ58NE1uhDGmTgTHpt6GJE23jq4ZSTbw39tuKuzqvLyH97l5kuQewQgzRsjDYr6cjzBgGCEqLpIBYhyynFB-2eWuzqjg4jq5CWEDgBEjaJC8Tg-q2atYuzZ1VdrWrU2D9a5xq9qoJvVqV5dptCGGtHI-jWubljZa87dYjhfLbOK-MnybXFWqCfbu9w6Tz6fpx-Qle3t_nk3Gb5khBGLGhNWcaa2NpkDBVIKCpQYbyI3QLEe6awgGQYy1fcIUAVQacQpaUE2GyezELZ3ayJ2vt8p_S6dqeSycX0nlY20aK2kBhhlTcC6AClAC9yhCc6pLgnjesR5PrN1eb21pbBu9as6g55-2XsuVO8iiIBQT0QFGJ4DxLgRvq_8tAnnUInststciOy3kBx5Qf3U</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><source>PubMed Central(OpenAccess)</source><creator>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</creator><creatorcontrib>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</creatorcontrib><description>Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples. Results. The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms. Conclusions. Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</description><identifier>ISSN: 1020-4989</identifier><identifier>EISSN: 1680-5348</identifier><identifier>DOI: 10.26633/RPSP.2020.149</identifier><language>eng</language><publisher>Organización Panamericana de la Salud</publisher><subject>betacoronavirus ; colombia ; coronavirus infections ; diagnostics ; Original Research ; serologic tests</subject><ispartof>Revista panamericana de salud pública, 2020-12, Vol.44 (149), p.1-9</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</citedby><cites>FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734239/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734239/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mercado, Marcela</creatorcontrib><creatorcontrib>Malagón-Rojas, Jeadran</creatorcontrib><creatorcontrib>Delgado, Gabriela</creatorcontrib><creatorcontrib>Rubio, Vivian Vanesa</creatorcontrib><creatorcontrib>Muñoz Galindo, Lida</creatorcontrib><creatorcontrib>Parra Barrera, Eliana L.</creatorcontrib><creatorcontrib>Gaviria, Paula</creatorcontrib><creatorcontrib>Zabaleta, Gabriela</creatorcontrib><creatorcontrib>Alarcon, Zonia</creatorcontrib><creatorcontrib>Arévalo, Adriana</creatorcontrib><creatorcontrib>Cifuentes, Helly Casallas</creatorcontrib><creatorcontrib>Estrada, Kelly</creatorcontrib><creatorcontrib>Puerto, Gloria</creatorcontrib><creatorcontrib>Herrera Sepúlveda, María T.</creatorcontrib><creatorcontrib>Rodríguez, Helena</creatorcontrib><creatorcontrib>Galindo, Marisol</creatorcontrib><creatorcontrib>Ospina Ramírez, Martha Lucía</creatorcontrib><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><title>Revista panamericana de salud pública</title><description>Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples. Results. The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms. Conclusions. Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</description><subject>betacoronavirus</subject><subject>colombia</subject><subject>coronavirus infections</subject><subject>diagnostics</subject><subject>Original Research</subject><subject>serologic tests</subject><issn>1020-4989</issn><issn>1680-5348</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV1LwzAUhosoOKe3XvcPdJ58NE1uhDGmTgTHpt6GJE23jq4ZSTbw39tuKuzqvLyH97l5kuQewQgzRsjDYr6cjzBgGCEqLpIBYhyynFB-2eWuzqjg4jq5CWEDgBEjaJC8Tg-q2atYuzZ1VdrWrU2D9a5xq9qoJvVqV5dptCGGtHI-jWubljZa87dYjhfLbOK-MnybXFWqCfbu9w6Tz6fpx-Qle3t_nk3Gb5khBGLGhNWcaa2NpkDBVIKCpQYbyI3QLEe6awgGQYy1fcIUAVQacQpaUE2GyezELZ3ayJ2vt8p_S6dqeSycX0nlY20aK2kBhhlTcC6AClAC9yhCc6pLgnjesR5PrN1eb21pbBu9as6g55-2XsuVO8iiIBQT0QFGJ4DxLgRvq_8tAnnUInststciOy3kBx5Qf3U</recordid><startdate>20201214</startdate><enddate>20201214</enddate><creator>Mercado, Marcela</creator><creator>Malagón-Rojas, Jeadran</creator><creator>Delgado, Gabriela</creator><creator>Rubio, Vivian Vanesa</creator><creator>Muñoz Galindo, Lida</creator><creator>Parra Barrera, Eliana L.</creator><creator>Gaviria, Paula</creator><creator>Zabaleta, Gabriela</creator><creator>Alarcon, Zonia</creator><creator>Arévalo, Adriana</creator><creator>Cifuentes, Helly Casallas</creator><creator>Estrada, Kelly</creator><creator>Puerto, Gloria</creator><creator>Herrera Sepúlveda, María T.</creator><creator>Rodríguez, Helena</creator><creator>Galindo, Marisol</creator><creator>Ospina Ramírez, Martha Lucía</creator><general>Organización Panamericana de la Salud</general><general>Pan American Health Organization</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20201214</creationdate><title>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</title><author>Mercado, Marcela ; Malagón-Rojas, Jeadran ; Delgado, Gabriela ; Rubio, Vivian Vanesa ; Muñoz Galindo, Lida ; Parra Barrera, Eliana L. ; Gaviria, Paula ; Zabaleta, Gabriela ; Alarcon, Zonia ; Arévalo, Adriana ; Cifuentes, Helly Casallas ; Estrada, Kelly ; Puerto, Gloria ; Herrera Sepúlveda, María T. ; Rodríguez, Helena ; Galindo, Marisol ; Ospina Ramírez, Martha Lucía</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>betacoronavirus</topic><topic>colombia</topic><topic>coronavirus infections</topic><topic>diagnostics</topic><topic>Original Research</topic><topic>serologic tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mercado, Marcela</creatorcontrib><creatorcontrib>Malagón-Rojas, Jeadran</creatorcontrib><creatorcontrib>Delgado, Gabriela</creatorcontrib><creatorcontrib>Rubio, Vivian Vanesa</creatorcontrib><creatorcontrib>Muñoz Galindo, Lida</creatorcontrib><creatorcontrib>Parra Barrera, Eliana L.</creatorcontrib><creatorcontrib>Gaviria, Paula</creatorcontrib><creatorcontrib>Zabaleta, Gabriela</creatorcontrib><creatorcontrib>Alarcon, Zonia</creatorcontrib><creatorcontrib>Arévalo, Adriana</creatorcontrib><creatorcontrib>Cifuentes, Helly Casallas</creatorcontrib><creatorcontrib>Estrada, Kelly</creatorcontrib><creatorcontrib>Puerto, Gloria</creatorcontrib><creatorcontrib>Herrera Sepúlveda, María T.</creatorcontrib><creatorcontrib>Rodríguez, Helena</creatorcontrib><creatorcontrib>Galindo, Marisol</creatorcontrib><creatorcontrib>Ospina Ramírez, Martha Lucía</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Revista panamericana de salud pública</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mercado, Marcela</au><au>Malagón-Rojas, Jeadran</au><au>Delgado, Gabriela</au><au>Rubio, Vivian Vanesa</au><au>Muñoz Galindo, Lida</au><au>Parra Barrera, Eliana L.</au><au>Gaviria, Paula</au><au>Zabaleta, Gabriela</au><au>Alarcon, Zonia</au><au>Arévalo, Adriana</au><au>Cifuentes, Helly Casallas</au><au>Estrada, Kelly</au><au>Puerto, Gloria</au><au>Herrera Sepúlveda, María T.</au><au>Rodríguez, Helena</au><au>Galindo, Marisol</au><au>Ospina Ramírez, Martha Lucía</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of nine serological rapid tests for the detection of SARS-CoV-2</atitle><jtitle>Revista panamericana de salud pública</jtitle><date>2020-12-14</date><risdate>2020</risdate><volume>44</volume><issue>149</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1020-4989</issn><eissn>1680-5348</eissn><abstract>Objective. To evaluate the operative capacity of nine serological rapid tests to detect the IgM/IgG antibodies response in serum from patients with SARS-CoV-2 in different clinical stages. Methods. A cross-sectional study of serological rapid tests was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. A total of 293 samples was used, including negatives, asymptomatic, and symptomatic serum samples. Results. The sensitivity of the evaluated tests was low and moderate in the groups of asymptomatic serum samples and the group of serums coming from patients with less than 11 days since the onset of the symptoms. The specificity for the anti-SARS-CoV-2 antibodies tests ranged between 86.5%-99% for IgM and 86.5%-99.5% for IgG. The sensitivity and the likelihood ratio were different according to the study groups. The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms. Conclusions. Serological tests are not an adequate strategy for the identification of asymptomatic and pre-symptomatic patients. Serological rapid tests for the detection of specific anti-SARS-CoV-2 antibodies can be used as a diagnostic aid, but diagnosis must be confirmed by RT-PCR. Rapid tests should be reserved for patients with symptoms lasting more than 11 days.</abstract><pub>Organización Panamericana de la Salud</pub><doi>10.26633/RPSP.2020.149</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1020-4989
ispartof Revista panamericana de salud pública, 2020-12, Vol.44 (149), p.1-9
issn 1020-4989
1680-5348
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_470c6cc78890490a92100f3454bd3185
source PubMed Central(OpenAccess)
subjects betacoronavirus
colombia
coronavirus infections
diagnostics
Original Research
serologic tests
title Evaluation of nine serological rapid tests for the detection of SARS-CoV-2
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20nine%20serological%20rapid%20tests%20for%20the%20detection%20of%20SARS-CoV-2&rft.jtitle=Revista%20panamericana%20de%20salud%20p%C3%BAblica&rft.au=Mercado,%20Marcela&rft.date=2020-12-14&rft.volume=44&rft.issue=149&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1020-4989&rft.eissn=1680-5348&rft_id=info:doi/10.26633/RPSP.2020.149&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_7734239%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c330t-69eb86bbbcb4040cf940e4c2c05c9b651bf9432093cee943224100fb1840b94b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true